Drug Type Small molecule drug |
Synonyms CT-2755, TQB 3454 |
Target |
Mechanism IDH1 inhibitors(Isocitrate dehydrogenase [NADP] cytoplasmic inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (CN) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced biliary tract cancer | Phase 3 | CN | 05 Sep 2023 | |
Hematologic Neoplasms | Phase 3 | - | - | |
Acute Myeloid Leukemia | Phase 2 | CN | 10 Jul 2023 | |
Myelodysplastic Syndromes | Phase 2 | CN | 10 Jul 2023 | |
Bile Duct Neoplasms | Phase 1 | CN | 01 Nov 2023 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 17 Aug 2020 | |
IDH1 Mutation Cholangiocarcinoma | IND Approval | CN | 22 Jun 2020 |
Phase 1 | 36 | avwvpjqbus(hohikuqjwo) = None sqvbeimvzr (czngrstzzg ) | Positive | 27 Jun 2024 |